Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Co-funded partnership · Running

CHIKVAX_CHIM Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).

Coordinator
Coalition for Epidemic Preparedness Innovations, Norway
Runs
1 June 2023 to 30 November 2028
Status
Running
EU funding
€70.0m
Total cost
€100.0m
Partners
1 organisations in 1 countries
Type
Co-funded partnership
Grant agreement
101126531

What the project is doing

In the project's own words, from its summary on CORDIS.

A Framework Partnership Agreement (FPA) between the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union (EU) was signed in April 2019, to finance and coordinate the development of new medical countermeasures to prevent and contain infectious disease epidemics, which are of particular concern to low- and middle-income countries. As part of the FPA, a call for proposals (CfP) was launched jointly with the EU and supported the preclinical development of Rift Valley Fever Virus vaccines and the late-stage development of Chikungunya virus vaccines (CHIKV).

While previous funding has led to the development of pre-licensure CHIK vaccines, in this current application we like to further advance our CHIK vaccine programme, and support CHIK vaccines that are near or have achieved regulatory licensure by supporting their clinical development into phase IV clinical trials to increase our understanding of the long-term safety, durability of protection, and effectiveness against virologically confirmed disease.

Furthermore, we would like to expand the use indication by supporting clinical trials in vulnerable populations, including children, immunosuppressed and pregnant women. As part of this grant application, we also like to launch a CfP on Controlled Human Infection Models (CHIM). The overall objective of the CHIM proposal is to support research projects that increase knowledge in vaccine-induced mucosal immunity and advance the development of transmission-blocking vaccines against coronaviruses and other potential respiratory viral threats.

The expected outcome of this CfP is to create a global network of experts conducting CHIM at a high level of consistency and reliability. This current grant application seeks to leverage €70M from Horizon Europe, which will be supplemented with €30M from CEPI making a pool of €100M. Awards will have a 36–48-month duration and will be administered by the CEPI secretariat.

Topics

Who is involved

OrganisationCityCountryRole
Coalition for Epidemic Preparedness InnovationsOsloNorwayCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI